List view / Grid view
Scientists have discovered active bacterial traces inside brain tumours, overturning assumptions about the brain’s sterility and opening up new possibilities for understanding – and potentially treating – gliomas and brain metastases.
Obecabtagene autoleucel (obe-cel) has demonstrated strong efficacy in treating relapsed B-cell leukemia, with high response rates and minimal side effects.
In this Q&A, Dr DaeYong Lee discusses how a new method for building up natural immune response could lead to new immunotherapy drugs with safer toxicity profiles.
Lactate producing bacteria is responsible for rewiring metabolic signalling pathways, causing resistance to radiation therapy.
Extracellular vesicles loaded with mRNA encoding interferon-gamma offers promise for treating difficult tumours.
A new pre-clinical study has utilised nanoparticles to attach immune-activating molecules to cancer cells.
The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) can block cell death, new research has shown, making it a cancer drug target.
Researchers have identified four unique subtypes of small-cell lung cancer (SCLC) following the characterisation of cell types.
Immunology study shows that NF-kappa B-inducing kinase (NIK) is critical to T cell metabolism and the antitumour immune response.
A murine study found histone deacetylase 3 (HDAC3) inhibitors reverse epigenetic changes caused by CREBBP mutations found in lymphomas and could be developed into a novel therapy.
President Trump has announced his intent to nominate Stephen Hahn as Commissioner of Food and Drugs at the Department of Health and Human Services.
An antibody has been developed to block a protein secreted by the cells surrounding ovarian and pancreatic cancer tumours.
A cellular pathway may reduce side effects and extend immunotherapy duration in patients with the most common form of liver cancer.
Researchers have discovered an immune regulator that appears to dictate glioblastoma progression by shutting down immune surveillance...
The enzyme protein kinase C delta (PKCδ) found in NSCLC tumors prevents tyrosine kinase inhibitors (TKIs) from forestalling cancer...
